Wagner M, Frost M, Frystyk J
Orphanet J Rare Dis. 2025; 20(1):93.
PMID: 40022110
PMC: 11871779.
DOI: 10.1186/s13023-025-03536-3.
Rao W, Li L, Wu L, Chai W, Li J
Medicine (Baltimore). 2025; 104(8):e41526.
PMID: 39993084
PMC: 11856978.
DOI: 10.1097/MD.0000000000041526.
Stolzel U, Jost L, Seehofer D, Egger-Heidrich K, Scheuermann U, Holig K
EJHaem. 2025; 6(1):e21092.
PMID: 39967799
PMC: 11833665.
DOI: 10.1002/jha2.1092.
Wei X, He Y, Yu Y, Tang S, Liu R, Guo J
Adv Sci (Weinh). 2025; 12(10):e2412850.
PMID: 39887888
PMC: 11905017.
DOI: 10.1002/advs.202412850.
Roach A, Barkley H, Rodriquez C, Burrow T, Anderson K, Shukla A
Eur J Hum Genet. 2024; .
PMID: 39663403
DOI: 10.1038/s41431-024-01758-w.
Porphyria cutanea tarda: a unique iron-related disorder.
Leaf R, Dickey A
Hematology Am Soc Hematol Educ Program. 2024; 2024(1):450-456.
PMID: 39644053
PMC: 11665602.
DOI: 10.1182/hematology.2024000664.
Hepatocellular Carcinoma in Acute Hepatic Porphyria: A Meta-Analysis of Observational Studies.
Singal A, Reddy R, Gudiwada M, Jasti J, Anderson K
Dig Dis Sci. 2024; 69(11):4268-4274.
PMID: 39438413
DOI: 10.1007/s10620-024-08661-w.
Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study.
Sardh E, Balwani M, Rees D, Anderson K, Jia G, Sweetser M
Orphanet J Rare Dis. 2024; 19(1):365.
PMID: 39363243
PMC: 11448181.
DOI: 10.1186/s13023-024-03284-w.
[Acute porphyria as a rare etiology of PRES].
Ramon Y Cajal Calvo J, Lopez Negredo D, Raymundez Valhondo J, Perez Abad L
Rev Fac Cien Med Univ Nac Cordoba. 2024; 81(3):598-607.
PMID: 39352843
PMC: 11536817.
DOI: 10.31053/1853.0605.v81.n3.44767.
Acute intermittent porphyria: a disease with low penetrance and high heterogeneity.
Lei J, Li S, Dong B, Yang J, Ren Y
Front Genet. 2024; 15:1374965.
PMID: 39188285
PMC: 11345236.
DOI: 10.3389/fgene.2024.1374965.
Novel mutation for porphyria cutanea tarda, type 2: a case report.
Soufleris S, Moore M, Phillips J, Netzel B, Rudnick S, Faust D
AME Case Rep. 2024; 8:67.
PMID: 39091564
PMC: 11292069.
DOI: 10.21037/acr-23-66.
Drug-associated porphyria: a pharmacovigilance study.
Wang Q, Zhuang J, Han B, Chen M, Zhao B
Orphanet J Rare Dis. 2024; 19(1):286.
PMID: 39090656
PMC: 11295309.
DOI: 10.1186/s13023-024-03294-8.
Ultra-Performance Liquid Chromatography (UPLC) Analysis of Heme Biosynthesis Intermediates.
Bergonia H, Phillips J
Methods Mol Biol. 2024; 2839:213-223.
PMID: 39008255
DOI: 10.1007/978-1-0716-4043-2_11.
Reducing diagnostic delays in acute hepatic porphyria using health records data and machine learning.
Bhasuran B, Schmolly K, Kapoor Y, Jayakumar N, Doan R, Amin J
J Am Med Inform Assoc. 2024; 32(1):63-70.
PMID: 38946554
PMC: 11648717.
DOI: 10.1093/jamia/ocae141.
Update on heme biosynthesis, tissue-specific regulation, heme transport, relation to iron metabolism and cellular energy.
Belot A, Puy H, Hamza I, Bonkovsky H
Liver Int. 2024; 44(9):2235-2250.
PMID: 38888238
PMC: 11625177.
DOI: 10.1111/liv.15965.
The context-dependent epigenetic and organogenesis programs determine 3D vs. 2D cellular fitness of MYC-driven murine liver cancer cells.
Yang J, Fang J, Singh S, Wells B, Wu Q, Janke L
Res Sq. 2024; .
PMID: 38853928
PMC: 11160912.
DOI: 10.21203/rs.3.rs-4390765/v1.
Editorial on the Special Issue "Heme Metabolism and Porphyria".
Pierro E, Barman-Aksozen J, Richard E
Life (Basel). 2024; 14(5).
PMID: 38792603
PMC: 11122142.
DOI: 10.3390/life14050581.
Crucial Involvement of Heme Biosynthesis in Vegetative Growth, Development, Stress Response, and Fungicide Sensitivity of .
Wang J, Cao Y, Shi D, Zhang Z, Li X, Chen C
Int J Mol Sci. 2024; 25(10).
PMID: 38791308
PMC: 11120706.
DOI: 10.3390/ijms25105268.
Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs.
Balogun O, Nejak-Bowen K
Semin Liver Dis. 2024; 44(2):209-225.
PMID: 38772406
PMC: 11268267.
DOI: 10.1055/s-0044-1787076.
The Growing Class of Novel RNAi Therapeutics.
Traber G, Yu A
Mol Pharmacol. 2024; 106(1):13-20.
PMID: 38719476
PMC: 11187687.
DOI: 10.1124/molpharm.124.000895.
